Cargando…

Characterization of etoposide- and cisplatin-chemoresistant retinoblastoma cell lines

Retinoblastoma (RB) is the most common malignant intraocular tumor in early childhood. Imminent chemotherapy resistance diminishes the clinical-therapeutic options and emphasizes the necessity for new therapeutic approaches. The present study aimed at characterizing and comparing etoposide and cispl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Busch, Maike, Papior, David, Stephan, Harald, Dünker, Nicole
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783599/ https://www.ncbi.nlm.nih.gov/pubmed/29192327 http://dx.doi.org/10.3892/or.2017.6100

Ejemplares similares

Tumor Suppressor Role of INPP4B in Chemoresistant Retinoblastoma
por: Miroschnikov, Natalia, et al.
Publicado: (2023)

Additive Effects of Retinoic Acid (RA) and Bone Morphogenetic Protein 4 (BMP-4) Apoptosis Signaling in Retinoblastoma Cell Lines
por: Müller, Patrick, et al.
Publicado: (2015)

Forced Trefoil Factor Family Peptide 3 (TFF3) Expression Reduces Growth, Viability, and Tumorigenicity of Human Retinoblastoma Cell Lines
por: Große-Kreul, Jan, et al.
Publicado: (2016)

Bone morphogenetic protein 4 (BMP4) signaling in retinoblastoma cells
por: Haubold, Maike, et al.
Publicado: (2010)

Retinoblastoma Cell Growth In Vitro and Tumor Formation In Ovo—Influence of Different Culture Conditions
por: Doege, Annika, et al.
Publicado: (2022)

p53, miR-34a and EMP1—Newly Identified Targets of TFF3 Signaling in Y79 Retinoblastoma Cells
por: Busch, Maike, et al.
Publicado: (2019)

Role of L1CAM in retinoblastoma tumorigenesis: identification of novel therapeutic targets
por: Dräger, Oliver, et al.
Publicado: (2021)

Expression Changes and Impact of the Extracellular Matrix on Etoposide Resistant Human Retinoblastoma Cell Lines
por: Reinhard, Jacqueline, et al.
Publicado: (2020)

Different transcriptome profiles between human retinoblastoma Y79 cells and an etoposide-resistant subline reveal a chemoresistance mechanism
por: Song, Wen-ping, et al.
Publicado: (2020)

Trefoil Family Factor Peptide 1—A New Biomarker in Liquid Biopsies of Retinoblastoma under Therapy
por: Busch, Maike Anna, et al.
Publicado: (2023)

Early Mechanisms of Chemoresistance in Retinoblastoma
por: Zhang, Michelle G., et al.
Publicado: (2022)

Schedule-dependent response of neuroblastoma cell lines to combinations of etoposide and cisplatin
por: Meczes, E L, et al.
Publicado: (2002)

ADAM10 and ADAM17—Novel Players in Retinoblastoma Carcinogenesis
por: Van Meenen, Dario, et al.
Publicado: (2022)

First line combination chemotherapy with cisplatin and etoposide in advanced ovarian cancer.
por: Athanassiou, A. E., et al.
Publicado: (1989)

TFF1 in Aqueous Humor—A Potential New Biomarker for Retinoblastoma
por: Busch, Maike Anna, et al.
Publicado: (2022)

Paclitaxel-etoposide-carboplatin/cisplatin versus etoposide-carboplatin/cisplatin as first-line treatment for combined small-cell lung cancer: a retrospective analysis of 62 cases
por: Li, Yue-Ya, et al.
Publicado: (2015)

Ribozymes targeting the tumor suppressor BRCA1 lead to increased chemosensitivity to cisplatin and etoposide and chemoresistance to microtubule-interfering agents in HBL100 breast cancer cell line
por: Lafarge, S, et al.
Publicado: (2000)

In vitro and in vivo Effects of Cisplatin and Etoposide in Combination on Small Cell Lung Cancer Cell Lines
por: Kondo, Hideki, et al.
Publicado: (1994)

An Exceptionally Favorable Response to Etoposide and Cisplatin
por: Valecha, Gautam, et al.
Publicado: (2015)

Toxicogenomics of nanoparticulate delivery of etoposide: potential impact on nanotechnology in retinoblastoma therapy
por: Mitra, Moutushy, et al.
Publicado: (2010)

Erratum to: Toxicogenomics of nanoparticulate delivery of etoposide: potential impact on nanotechnology in retinoblastoma therapy
por: Mitra, Moutushy, et al.
Publicado: (2011)

Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer
por: Sun, Yan, et al.
Publicado: (2016)

Establishment and Characterization of Carboplatin-Resistant Retinoblastoma Cell Lines
por: Cho, Chang Sik, et al.
Publicado: (2022)

Carboplatin- and Etoposide-Loaded Lactoferrin Protein Nanoparticles for Targeting Cancer Stem Cells in Retinoblastoma In Vitro
por: Narayana, Revu V. L., et al.
Publicado: (2021)

Recurrent Metastatic Choriocarcinoma Responsive to Etoposide and Cisplatin with Etoposide, Methotrexate, and Dactinomycin: A Case Report
por: Das, Sunil Kumar, et al.
Publicado: (2022)

Retinoblastoma protein regulates the crosstalk between autophagy and apoptosis, and favors glioblastoma resistance to etoposide
por: Biasoli, D, et al.
Publicado: (2013)

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin
por: Mitry, E, et al.
Publicado: (1999)

Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines.
por: Zangemeister-Wittke, U., et al.
Publicado: (1998)

Characterization of an Etoposide‐resistant Human K562 Cell Line, K/eto
por: Sugawara, Isamu, et al.
Publicado: (1991)

Erratum in: Carboplatin- and Etoposide-Loaded Lactoferrin Protein Nanoparticles for Targeting Cancer Stem Cells in Retinoblastoma In Vitro
Publicado: (2022)

L1 increases adhesion-mediated proliferation and chemoresistance of retinoblastoma
por: Jo, Dong Hyun, et al.
Publicado: (2017)

Outcome of treatment with EMA/EP (etoposide methotrexate and actinomycin-D/ etoposide and cisplatin) regimen in gestational trophoblastic neoplasia
por: Aminimoghaddam, Soheila, et al.
Publicado: (2018)

A Phase III Randomized Study Comparing a Chemotherapy with Cisplatin and Etoposide to a Etoposide Regimen without Cisplatin for Patients with Extensive Small-Cell Lung Cancer
por: Berghmans, Thierry, et al.
Publicado: (2017)

Carboplatin versus cisplatin in combination with etoposide in the first-line treatment of small cell lung cancer: a pooled analysis
por: Jiang, Shiyu, et al.
Publicado: (2021)

Cisplatin for cancer therapy and overcoming chemoresistance
por: Ranasinghe, Ranmali, et al.
Publicado: (2022)

Activity- and schedule-dependent interactions of paclitaxel, etoposide and hydroperoxy-ifosfamide in cisplatin-sensitive and -refractory human ovarian carcinoma cell lines.
por: Klaassen, U., et al.
Publicado: (1996)

Ascorbate-induced oxidative stress mediates TRP channel activation and cytotoxicity in human etoposide-sensitive and -resistant retinoblastoma cells
por: Oronowicz, Jakub, et al.
Publicado: (2020)

Comparison of Ifosfamide, Carboplatin and Etoposide versus Etoposide, Steroid, and Cytarabine Cisplatin as Salvage Chemotherapy in Patients with Refractory or Relapsed Hodgkin's lymphoma
por: Mehrzad, Valiollah, et al.
Publicado: (2017)

Photochemical Internalization of Etoposide Using Dendrimer Nanospheres Loaded with Etoposide and Protoporphyrin IX on a Glioblastoma Cell Line
por: Lin, Martin Hsiu-Chu, et al.
Publicado: (2021)

Addition of intraperitoneal cisplatin and etoposide to first-line chemotherapy for advanced ovarian cancer: a randomised, phase 2 trial
por: Shi, Tingyan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_k947jrrvu0s0k4if18p1dorvn5